Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

One-third of high-risk CLL patients received treatment counter to recommendations

Key clinical point: Prognostic marker analysis using FISH is infrequently performed.

Major finding: High-risk groups of patients with del(17p) and mutated TP53, received chemoimmunotherapy 34% and 26% of the time, respectively.

Study details: Retrospective database analysis of 840 patients from the informCLL registry.

Disclosures: The study was sponsored by an AbbVie Company and Janssen. The authors reported consulting and grants from these and other pharmaceutical companies.

Citation:

Mato AR et al. Clin Lymphoma Myeloma Leuk. 2020;20(3):174-83.